Patient preferences in the medical product lifecycle

Jennifer Whitty; Esther de Bekker-Grob; Nigel Cook; Fern Terris-Prestholt; I Cleemput; Michael Frank Drummond; Rocco Falchetto; Hans Hillege

doi:10.1007/s40271-019-00400-y

Patient preferences in the medical product lifecycle

Jennifer Whitty, Esther de Bekker-Grob, Nigel Cook, Fern Terris-Prestholt, I Cleemput, Michael Frank Drummond, Rocco Falchetto, Hans Hillege

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Abstract

Taking into consideration the patient voice has not only become increasingly important for the companies that develop new medical products, but also for the authorities that assess, regulate and decide which medical products are effective, safe, well tolerated and cost-effective. Patient preference studies can complement patient narratives and qualitative insights in a quantitative manner and provide understanding of the trade-offs patients are willing to make. However, what is currently missing is a shared understanding among key stakeholders (industry, regulatory authorities, health technology assessment bodies, reimbursement agencies, clinicians and patient organisations) about when and how to consider patient preferences in the medical product lifecycle. This commentary captures important opinions on patient preferences and the medical product lifecycle that were discussed in the rare opportunity to gather key opinion leaders from a wide range of perspectives that was offered by the symposium on “Patient preferences in the medical product lifecycle” held in Basel, Switzerland in July 2019. The symposium was jointly organised by the International Academy of Health Preference Research (IAHPR) and the Innovative Medicine Initiative research project ‘Patient Preferences in Benefit and Risk Assessments during the Treatment Life Cycle’ (PREFER).

Original language	English
Pages (from-to)	1-4
Number of pages	4
Journal	The Patient - Patient-Centered Outcomes Research
Early online date	29 Nov 2019
DOIs	https://doi.org/10.1007/s40271-019-00400-y
Publication status	E-pub ahead of print - 29 Nov 2019

Bibliographical note

© Springer Nature Switzerland AG 2019. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.

Access to Document

10.1007/s40271-019-00400-y

JW EdB NC etal Patient prefs The Patient final submitd 151119
© Springer Nature Switzerland AG 2019. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.
Accepted author manuscript, 601 KB

Cite this

@article{374dfbe2f3f0404b8124ce4ef51f1c52,

title = "Patient preferences in the medical product lifecycle",

abstract = "Taking into consideration the patient voice has not only become increasingly important for the companies that develop new medical products, but also for the authorities that assess, regulate and decide which medical products are effective, safe, well tolerated and cost-effective. Patient preference studies can complement patient narratives and qualitative insights in a quantitative manner and provide understanding of the trade-offs patients are willing to make. However, what is currently missing is a shared understanding among key stakeholders (industry, regulatory authorities, health technology assessment bodies, reimbursement agencies, clinicians and patient organisations) about when and how to consider patient preferences in the medical product lifecycle. This commentary captures important opinions on patient preferences and the medical product lifecycle that were discussed in the rare opportunity to gather key opinion leaders from a wide range of perspectives that was offered by the symposium on “Patient preferences in the medical product lifecycle” held in Basel, Switzerland in July 2019. The symposium was jointly organised by the International Academy of Health Preference Research (IAHPR) and the Innovative Medicine Initiative research project {\textquoteleft}Patient Preferences in Benefit and Risk Assessments during the Treatment Life Cycle{\textquoteright} (PREFER).",

author = "Jennifer Whitty and {de Bekker-Grob}, Esther and Nigel Cook and Fern Terris-Prestholt and I Cleemput and Drummond, {Michael Frank} and Rocco Falchetto and Hans Hillege",

note = "{\textcopyright} Springer Nature Switzerland AG 2019. This is an author-produced version of the published paper. Uploaded in accordance with the publisher{\textquoteright}s self-archiving policy. Further copying may not be permitted; contact the publisher for details.",

year = "2019",

month = nov,

day = "29",

doi = "10.1007/s40271-019-00400-y",

language = "English",

pages = "1--4",

journal = "The Patient - Patient-Centered Outcomes Research",

}

TY - JOUR

T1 - Patient preferences in the medical product lifecycle

AU - Whitty, Jennifer

AU - de Bekker-Grob, Esther

AU - Cook, Nigel

AU - Terris-Prestholt, Fern

AU - Cleemput, I

AU - Drummond, Michael Frank

AU - Falchetto, Rocco

AU - Hillege, Hans

N1 - © Springer Nature Switzerland AG 2019. This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.

PY - 2019/11/29

Y1 - 2019/11/29

N2 - Taking into consideration the patient voice has not only become increasingly important for the companies that develop new medical products, but also for the authorities that assess, regulate and decide which medical products are effective, safe, well tolerated and cost-effective. Patient preference studies can complement patient narratives and qualitative insights in a quantitative manner and provide understanding of the trade-offs patients are willing to make. However, what is currently missing is a shared understanding among key stakeholders (industry, regulatory authorities, health technology assessment bodies, reimbursement agencies, clinicians and patient organisations) about when and how to consider patient preferences in the medical product lifecycle. This commentary captures important opinions on patient preferences and the medical product lifecycle that were discussed in the rare opportunity to gather key opinion leaders from a wide range of perspectives that was offered by the symposium on “Patient preferences in the medical product lifecycle” held in Basel, Switzerland in July 2019. The symposium was jointly organised by the International Academy of Health Preference Research (IAHPR) and the Innovative Medicine Initiative research project ‘Patient Preferences in Benefit and Risk Assessments during the Treatment Life Cycle’ (PREFER).

AB - Taking into consideration the patient voice has not only become increasingly important for the companies that develop new medical products, but also for the authorities that assess, regulate and decide which medical products are effective, safe, well tolerated and cost-effective. Patient preference studies can complement patient narratives and qualitative insights in a quantitative manner and provide understanding of the trade-offs patients are willing to make. However, what is currently missing is a shared understanding among key stakeholders (industry, regulatory authorities, health technology assessment bodies, reimbursement agencies, clinicians and patient organisations) about when and how to consider patient preferences in the medical product lifecycle. This commentary captures important opinions on patient preferences and the medical product lifecycle that were discussed in the rare opportunity to gather key opinion leaders from a wide range of perspectives that was offered by the symposium on “Patient preferences in the medical product lifecycle” held in Basel, Switzerland in July 2019. The symposium was jointly organised by the International Academy of Health Preference Research (IAHPR) and the Innovative Medicine Initiative research project ‘Patient Preferences in Benefit and Risk Assessments during the Treatment Life Cycle’ (PREFER).

U2 - 10.1007/s40271-019-00400-y

DO - 10.1007/s40271-019-00400-y

M3 - Article

SP - 1

EP - 4

JO - The Patient - Patient-Centered Outcomes Research

JF - The Patient - Patient-Centered Outcomes Research

ER -